Eli Lilly & Co., Pfizer Inc. and Johnson & Johnson secured spots on China’s first innovative drug catalog, opening a new market channel and boosting sales prospects for costly, cutting-edge treatments.
In all, 19 medicines made the list — a formulary of drugs deemed too expensive for state insurance but recommended for commercial health coverage — officials said in Guangzhou on Sunday. The drugs are for a range of conditions including cancer and Alzheimer’s, as well as rare genetic disorders.
